PSMP/MSMP通过CCR2促进肝纤维化并可作为新型治疗靶点
本研究探讨了PSMP/MSMP在肝纤维化/肝硬化中的表达与作用。在患者组织及三种小鼠模型中,PSMP高表达;Psmp缺失或使用PSMP中和抗体3D5可减轻肝损伤和纤维化,其作用依赖于CCR2。PSMP通过促进巨噬细胞浸润、M1极化及直接激活肝星状细胞促进纤维化。
要点
- PSMP在多种病因的纤维化/肝硬化组织及三种小鼠纤维化模型中高表达。
- Psmp缺失或PSMP中和抗体3D5可减轻CCl4诱导的肝损伤和纤维化。
- PSMP通过CCR2促进巨噬细胞浸润、M1极化及肝星状细胞活化。
核心结论
- PSMP通过其受体CCR2增强肝纤维化,是肝纤维化治疗的潜在 attractive 靶点。
研究设计与样本
- 研究检测了纤维化/肝硬化患者组织及三种小鼠肝纤维化模型(CCl4、胆管结扎、DDC饮食)中PSMP的表达。
- 利用Psmp-/-小鼠及野生型小鼠中PSMP抗体治疗评估PSMP的作用。
- 体外研究PSMP对巨噬细胞和肝星状细胞的直接效应。
主要发现
- PSMP在不同病因的纤维化/肝硬化患者组织及三种实验小鼠纤维化模型中高表达。
- 损伤相关分子模式分子HMGB-1和IL-33诱导肝细胞产生PSMP。
- Psmp缺失显著改善肝损伤和纤维化;在CCl4诱导的肝损伤中,Psmp-/-小鼠肝脏巨噬细胞和CCR2+单核细胞浸润显著减少,促炎细胞因子显著降低。
- 腺相关病毒8载体在Psmp-/-小鼠肝脏过表达人PSMP可以CCR2依赖的方式逆转CCl4诱导的肝损伤和纤维化减轻。
- PSMP中和抗体3D5治疗可预防CCl4诱导的小鼠肝损伤和纤维化;PSMP直接促进巨噬细胞M1极化和LX-2细胞活化。
临床怎么用
- PSMP及其中和抗体3D5可能作为肝纤维化治疗的潜在靶点和药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: C-C motif chemokine receptor 2 (CCR2) has been recognized as a promising target for the treatment of liver fibrosis. PC3-secreted microprotein (PSMP)/microseminoprotein (MSMP) is a novel chemotactic cytokine and its receptor is CCR2. In the present study we investigated the expression and role of PSMP in liver fibrosis/cirrhosis. METHODS: PSMP expression was studied in patients with fibrosis/cirrhosis and in 3 murine models of liver fibrosis, including mice treated with carbon tetrachloride (CCl4), bile-duct ligation, or a 5-diethoxycarbonyl-1,4-dihydrocollidine diet. The role of PSMP was evaluated in Psmp-/- mice and after treatment with a PSMP antibody in wild-type mice. The direct effects of PSMP on macrophages and hepatic stellate cells were studied in vitro. RESULTS: In this study, we found that PSMP was highly expressed in fibrotic/cirrhotic tissues from patients with different etiologies of liver disease and in the 3 experimental mouse models of fibrosis. Damage-associated molecular pattern molecules HMGB-1 and IL-33 induced hepatocytes to produce PSMP. PSMP deficiency resulted in a marked amelioration of hepatic injury and fibrosis. In CCl4-induced hepatic injury, the infiltration of macrophages and CCR2+ monocytes into the liver was significantly decreased in Psmp-/- mice. Consistent with the decreased levels of intrahepatic macrophages, proinflammatory cytokines were significantly reduced. Moreover, adeno-associated virus-8 vectors successfully overexpressing human PSMP in Psmp-/- mouse livers could reverse the attenuation of liver injury and fibrosis induced by CCl4 in a CCR2-dependent manner. Treatment with a specific PSMP-neutralizing antibody, 3D5, prevented liver injury and fibrosis induced by CCl4 in mice. At the cellular level, PSMP directly promoted M1 polarization of macrophages and activation of LX-2 cells. CONCLUSION: PSMP enhances liver fibrosis through its receptor, CCR2. PSMP is a potentially attractive therapeutic target for the treatment of patients with liver fibrosis. LAY SUMMARY: Our present study identifies the essential role of the protein PSMP for the development and progression of liver fibrosis in humans and mice. PSMP promotes liver fibrosis through inflammatory macrophage infiltration, polarization and production of proinflammatory cytokines, as well as direct activation of hepatic stellate cells via its receptor CCR2. A PSMP antibody can significantly reduce liver fibrosis development in vivo. These findings indicate that PSMP is a potential therapeutic target and its antibody is a potential therapeutic agent for the treatment of liver fibrosis.
引用
- She S, Wu X, Zheng D, et al. PSMP/MSMP promotes hepatic fibrosis through CCR2 and represents a novel therapeutic target. J Hepatol. 2019. PMID: 31813573. doi:10.1016/j.jhep.2019.09.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。